Catch up with Ipsen and Citeline to hear the latest expertise and insights on the state of play for deal-making, cutting through the noise to find the right deal and securing competitive alliances.
Philippe Lopes-Fernandes, Ipsen’s Executive Vice President and Chief Business Officer, outlines the company’s strategy and shares his expertise on what both parties must bring to the table for a successful biopharma deal today. Citeline demonstrates how to make the most out of data to find the competitive edge in a busy marketplace. This webinar brings together thought leadership and data expertise to better understand global business development strategies in the present and for the future.
This webinar took place on 31 October, however you can now watch the recording at your leisure once you've registered to view.
Executive Vice President and Chief Business Officer
Ipsen
Philippe Lopes-Fernandes
With more than 20 years of leadership and expertise in global business development and acquisitions within the pharmaceutical industry, Philippe is responsible for driving Ipsen’s external innovation strategy and strengthening alliances across its key therapeutic areas of oncology, neuroscience and rare disease. He has an extensive track record of creating successful business development deals in multiple therapeutic areas in Europe, Asia and North America.
Prior to joining Ipsen, Philippe worked at Merck KGaA where he was the Senior Vice President, Global Head of Business Development and Alliance Management. Before that, he held a variety of roles at Merck KGaA in Business Development, Mergers and Acquisitions, Finance and Marketing in Germany, France, Portugal, Switzerland and the United States.Philippe received his degree from the Institut Supérieur de Gestion (ISG) in Paris in 1994. He is a French External Trade advisor (Conseiller du Commerce Extérieur) and board member of several companies.
Lucie Ellis-Taitt
Executive Editor | In Vivo
Citeline
Lucie Ellis-Taitt
Lucie Ellis-Taitt has been reporting on the biopharma and medtech industries for more than a decade. As executive editor for In Vivo, she is responsible for setting the publication’s agenda, managing a team of experienced journalists and reporting on the most important topics for In Vivo’s audience of industry leaders.
Lucie was previously a senior writer for Scrip. She is skilled in research, analysis, editing, data visualization, and feature and news writing.
Sara Golpeykar
Solution Specialist
Citeline
Sara Golpeykar
Sara Golpeykar is a Solution Specialist for Citeline’s Commercial team, helping Pharma companies define winning commercial strategies. Sara’s works closely with clients to understand key competitor trends, market dynamics, and future SoCs to build effective strategic plans for target product profiling, indication prioritisation, market opportunity assessment, In and out licensing, and additional cash-flow.
Sara has previously worked as a Senior Immunology Analysts for a pharma intelligence information provider, and has a BSc (Hons) in Pharmacology and a MSc in Drug Development from King's College London.
